1 / 20

Global And China Osteoporosis Drugs Market Analysis (2020-2027)

Read here the market research report on the u201cChina Osteoporosis Drugs Market" published by CMI Team

kunalbhuta
Download Presentation

Global And China Osteoporosis Drugs Market Analysis (2020-2027)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS(2020-2027) • Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid, Others), Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospitals Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, China, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

  3. Osteoporosis is characterized by micro-architectural deterioration of bone tissue leading to low bone mass and bone fragility, especially in the older age. The condition affects both sexes; however women are more prone to it, especially post-menopause when bone loss is accelerated due to reduced estrogen, which helps protect the bones.

  4. Statistics: • The global and China osteoporosis drugs market is estimated to account for US$ 17.1 Bn in terms of value by the end of 2027.

  5. Global and China Osteoporosis Drugs Market: Drivers • Increasing prevalence of osteoporosis is expected to propel growth of the global and China osteoporosis drugs market over the forecast period. For instance, according to the study, ‘The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey’, published in October 2019, in The Journal of Bone and Mineral Research, the age-standardized prevalence of osteoporosis at the spine or hip was 6.46% and 29.13% for men and women aged 50 years and older, respectively. A total of 10.9 million men and 49.3 million women in China were estimated to have osteoporosis. • Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the United Nations, Department of Economic and Social Affairs, Population Division, the geriatric population in China is expected to reach 246,986 thousands in 2030 from 164,487 thousands in 2019.

  6. Statistics: • North America held dominant position in the global and China osteoporosis drugs market in 2019, accounting for 38.5% share in terms of value, followed by Europe and Asia Pacific, respectively.

  7. Figure 1: Global and China Osteoporosis Drugs Market Share (%) Value, By Region, 2019

  8. Global and China Osteoporosis Drugs Market: Restraints • Adverse effects of osteoporosis drugs are expected to hinder growth of the market. For instance, consumption of alendronate may lead to stomach pain, acid reflux, constipation, diarrhea, upset stomach, nausea, or muscle and joint pain. • Moreover, low awareness and diagnosis of osteoporosis, especially in emerging economies is also expected to limit the market growth.

  9. Global and China Osteoporosis Drugs Market: Opportunities  • R&D in novel therapeutics is expected to offer lucrative growth opportunities for players in the global and China osteoporosis drugs market. For instance, in June 2020, researchers from School of Medicine CHA University, South Korea, reported that Tauroursodeoxycholic acid, the U.S. FDA-approved hydrophilic bile acid for the treatment of chronic cholestatic liver disease, may provide a favorable effect on bones and could be used for the prevention and treatment of osteoporosis. • Moreover, increasing number of smokers is also expected to aid in growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.

  10. Statistics: • The global and China osteoporosis drugs market was valued at US$ 12.7 Bn in 2019 and is forecast to reach a value of US$ 17.1 Bn by 2027 at a CAGR of 3.8% between 2020 and 2027.

  11. Figure 2: Global and China Osteoporosis Drugs Market Value (US$ Bn), 2016 – 2027

  12. Market Trends/Key Takeaways • Major organizations are focused on reducing the burden of osteoporosis. For instance, in June 2020, The International Osteoporosis Foundation partnered with Amgen and UCB, a global biopharmaceutical company, in collaboration with the University of Oxford, to support its Capture the Fracture program, which aims to reduce hip and vertebral fractures by 25% by 2025.

  13. Approval and launch of AI-based products to predict osteoporosis is expected to aid in growth of the market. For instance, in May 2020, Zebra Medical Vision received FDA 510(k) clearance for its Vertebral Compression Fractures product, which automatically identifies findings suggestive of compression fractures, which enables clinicians to place patients that are at risk of osteoporosis in treatment pathways.

  14. Global and China Osteoporosis Drugs Market: Competitive Landscape • Major players operating in the global and China osteoporosis drugs market include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.

  15. Global and China Osteoporosis Drugs Market: Key Developments • Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Teijin Pharma Limited, a partner of Radius Health, Inc., submitted a New Drug Application for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at high risk for fractures. • Similarly, in April 2019, Amgen and UCB received the U.S. Food and Drug Administration approval for EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

  16. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference: https://www.coherentmarketinsights.com/market-insight/global-and-china-osteoporosis-drugs-market-4018

  17. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  18. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  19. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related